IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 5973 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (660 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed813    
    Printed34    
    Emailed0    
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
NET LETTER
Year : 2019  |  Volume : 85  |  Issue : 4  |  Page : 440

Nevus sebaceus on the face: Experience with photodynamic therapy in adults and children


Department of Dermatology, Ramon y Cajal University Hospital, Madrid, Spain

Date of Web Publication7-Jun-2019

Correspondence Address:
Dr. Oscar Muņoz Moreno-Arrones
Ramón y Cajal University Hospital, Ctra, De Colmenar Viejo, Km. 9100, 28034 Madrid
Spain
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdvl.IJDVL_1162_16

Rights and Permissions



How to cite this article:
Moreno-Arrones OM, Perez-Garcia B. Nevus sebaceus on the face: Experience with photodynamic therapy in adults and children. Indian J Dermatol Venereol Leprol 2019;85:440

How to cite this URL:
Moreno-Arrones OM, Perez-Garcia B. Nevus sebaceus on the face: Experience with photodynamic therapy in adults and children. Indian J Dermatol Venereol Leprol [serial online] 2019 [cited 2019 Aug 17];85:440. Available from: http://www.ijdvl.com/text.asp?2019/85/4/440/238089




Sir,

Nevus sebaceus is a rare hamartoma of the skin that can grow and thicken during puberty and in some cases undergo malignant transformation. It has been linked to somatic mosaic mutations in either the KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) or HRAS (Harvey Rat Sarcoma Viral Oncogene Homolog) genes. Sebaceous nevi typically present as yellow-orange oval or linear well-defined plaques affecting predominantly the scalp. Unfortunately, sebaceous nevi also have a tendency to appear on the face leading to patients experiencing low self-esteem due to esthetic considerations. Although risk of malignancy is the main reason for removal of these lesions, incidence of malignant transformation has not been established yet and remains a topic of controversy.[1],[2] Nevertheless, sebaceous nevi may also require treatment to improve esthetics. Despite the fact that complete excision of the lesion is curative, it may leave disfiguring scars. For this reason, other therapeutic approaches such as photodynamic therapy, carbon dioxide laser or dermabrasion have been proposed with mixed results.[3],[4],[5] A previous report studied the efficacy and safety of photodynamic therapy on 12 sebaceous nevi with promising results (58% patients showed moderate improvement, 25% showed mild improvement and 17% had a marked improvement).[5] However, before each photodynamic therapy session, the authors performed carbon dioxide laser ablation on the lesions. As some patients received numerous photodynamic therapy and carbon dioxide laser sessions, it may be incorrect to conclude that the efficacy of the treatment was solely due to photodynamic therapy.

This study describes the clinical outcome and adverse effects of photodynamic therapy applied to sebaceous nevi affecting esthetically concerning areas such as the eyelids or the face. The rationale behind using photodynamic therapy for sebaceous nevi is the selectivity of methyl aminolevulinate for the sebaceous glands. This fact is further evidenced by observing the greater fluorescence of these lesions in relation to the surrounding healthy skin after the application of the photosensitizer [Figure 1].
Figure 1: Nevus sebaceus on the left cheek. Clinical and ultraviolet pictures of the lesion and results after the last photodynamic therapy session. Note the decrease in fluorescence due to the improvement of the nevus sebaceous

Click here to view


A retrospective descriptive study of six patients with sebaceous nevi on the face treated with photodynamic therapy was conducted at our hospital. A dermatologist not involved in the study visually assessed clinical improvement. Efficacy was evaluated at the end of the treatment. In addition, patients subjectively evaluated the treatment based on pain during procedure, esthetic outcome and treatment duration. This was graded from 0 (“awful treatment”) to 5 (“excellent treatment”).

Procedure consisted of the application of a photosensitizer, topical methyl aminolevulinate (Metvix®, Galderma, France), to the lesions, followed by occlusion with a polyurethane film. Incubation time was 3 h. Total light dose was 37 J/cm2. Depending on post-treatment inflammation and high fluorescence, incubation time was reduced in the following sessions to 2 h. After incubation, the lesions were irradiated with a 630 nm light emitting diode device without anesthesia.

Time between each photodynamic therapy session was 3 weeks. Treatment was stopped when either the patient was satisfied with the clinical result or demanded surgical removal of the lesion.

[Table 1] summarizes the results of the study. Mean age of patients was 16.8 years (range 5–31). Two patients had received laser treatment in the past. Five patients (83.3%) achieved significant improvement (at least a 50% reduction in size) at the end of their treatment [Figure 1], two of them experienced more than 80% reduction in size compared to baseline. The patient with sebaceous nevi affecting the eyelid experienced only minor improvement (30% reduction in size). Mean score for patient's satisfaction was 4.08 (range 3–5). Mean number of sessions per patient was 7.6 (4–13). Adverse events were rare and transient: One patient experienced an urticaria-like reaction and other suffered temporary hyperpigmentation. Neither recurrence nor malignant transformation was observed during the follow-up (14–125 months, mean 55.8). All the patients tolerated the treatment well. It is interesting to highlight that the patients that achieved significant improvement did so after at least three sessions. Only one patient demanded surgical removal of the lesion.
Table 1: Demographic and clinical characteristics of the patients

Click here to view


This study shows that photodynamic therapy offers good clinical response with a low risk of adverse events and could be considered as an adjuvant or alternative therapy in sebaceous nevi affecting esthetically concerning areas. Main limitations of this study were the low number of patients involved, the absence of a control group or comparison between topical photosensitizers, different intensities of light and other treatments. Better-designed controlled studies are needed to characterize optimal therapeutic approach for these cases.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Rosen H, Schmidt B, Lam HP, Meara JG, Labow BI. Management of nevus sebaceous and the risk of basal cell carcinoma: An 18-year review. Pediatr Dermatol 2009;26:676-81.  Back to cited text no. 1
    
2.
Moody MN, Landau JM, Goldberg LH. Nevus sebaceous revisited. Pediatr Dermatol 2012;29:15-23.  Back to cited text no. 2
    
3.
Kim HS, Jun JH, Lee JY. Photodynamic therapy of facial nevus sebaceous. Photodermatol Photoimmunol Photomed 2010;26:98-100.  Back to cited text no. 3
    
4.
Calzavara-Pinton PG, Rossi MT, Sala R; Italian Group for Photodynamic Therapy. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 2: Oncologic and infectious indications. Photochem Photobiol Sci 2013;12:158-65.  Back to cited text no. 4
    
5.
In SI, Lee JY, Kim YC. Topical photodynamic therapy for nevus sebaceous on the face. Eur J Dermatol 2010;20:590-2.  Back to cited text no. 5
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow